nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—Antazoline—Phenytoin—epilepsy syndrome	0.356	1	CrCrCtD
Phentolamine—ADRA2A—epilepsy syndrome	0.333	1	CbGaD
Phentolamine—NISCH—telencephalon—epilepsy syndrome	0.00117	0.0469	CbGeAlD
Phentolamine—ADRA1A—hindbrain—epilepsy syndrome	0.0011	0.0442	CbGeAlD
Phentolamine—ADRA1D—forebrain—epilepsy syndrome	0.00106	0.0426	CbGeAlD
Phentolamine—ADRA1D—telencephalon—epilepsy syndrome	0.000975	0.0392	CbGeAlD
Phentolamine—NISCH—medulla oblongata—epilepsy syndrome	0.000918	0.0369	CbGeAlD
Phentolamine—NISCH—midbrain—epilepsy syndrome	0.000839	0.0337	CbGeAlD
Phentolamine—NISCH—spinal cord—epilepsy syndrome	0.000819	0.0329	CbGeAlD
Phentolamine—SIGMAR1—telencephalon—epilepsy syndrome	0.00068	0.0273	CbGeAlD
Phentolamine—NISCH—cerebellum—epilepsy syndrome	0.000649	0.0261	CbGeAlD
Phentolamine—ADRA1A—brainstem—epilepsy syndrome	0.000631	0.0253	CbGeAlD
Phentolamine—ADRA1B—head—epilepsy syndrome	0.000621	0.0249	CbGeAlD
Phentolamine—ADRA1A—forebrain—epilepsy syndrome	0.000609	0.0245	CbGeAlD
Phentolamine—ADRA1D—head—epilepsy syndrome	0.000607	0.0244	CbGeAlD
Phentolamine—Naphazoline—ADRA2A—epilepsy syndrome	0.000596	1	CrCbGaD
Phentolamine—ADRA1B—nervous system—epilepsy syndrome	0.000589	0.0236	CbGeAlD
Phentolamine—ADRA1D—nervous system—epilepsy syndrome	0.000576	0.0231	CbGeAlD
Phentolamine—ADRA1B—central nervous system—epilepsy syndrome	0.000567	0.0228	CbGeAlD
Phentolamine—ADRA1A—telencephalon—epilepsy syndrome	0.00056	0.0225	CbGeAlD
Phentolamine—ADRA1D—central nervous system—epilepsy syndrome	0.000554	0.0223	CbGeAlD
Phentolamine—SIGMAR1—medulla oblongata—epilepsy syndrome	0.000534	0.0214	CbGeAlD
Phentolamine—ADRA2C—telencephalon—epilepsy syndrome	0.000534	0.0214	CbGeAlD
Phentolamine—NISCH—brain—epilepsy syndrome	0.000527	0.0212	CbGeAlD
Phentolamine—SIGMAR1—midbrain—epilepsy syndrome	0.000488	0.0196	CbGeAlD
Phentolamine—SIGMAR1—spinal cord—epilepsy syndrome	0.000476	0.0191	CbGeAlD
Phentolamine—ADRA2A—forebrain—epilepsy syndrome	0.000463	0.0186	CbGeAlD
Phentolamine—ADRA1B—brain—epilepsy syndrome	0.00045	0.0181	CbGeAlD
Phentolamine—ADRA1D—brain—epilepsy syndrome	0.00044	0.0177	CbGeAlD
Phentolamine—ADRA2A—telencephalon—epilepsy syndrome	0.000426	0.0171	CbGeAlD
Phentolamine—ADRA2C—medulla oblongata—epilepsy syndrome	0.000419	0.0168	CbGeAlD
Phentolamine—ADRA2C—midbrain—epilepsy syndrome	0.000383	0.0154	CbGeAlD
Phentolamine—SIGMAR1—cerebellum—epilepsy syndrome	0.000378	0.0152	CbGeAlD
Phentolamine—ADRA2C—spinal cord—epilepsy syndrome	0.000374	0.015	CbGeAlD
Phentolamine—ADRA1A—head—epilepsy syndrome	0.000349	0.014	CbGeAlD
Phentolamine—ADRA2A—medulla oblongata—epilepsy syndrome	0.000335	0.0134	CbGeAlD
Phentolamine—ADRA2C—head—epilepsy syndrome	0.000332	0.0133	CbGeAlD
Phentolamine—ADRA1A—nervous system—epilepsy syndrome	0.000331	0.0133	CbGeAlD
Phentolamine—ADRA1A—central nervous system—epilepsy syndrome	0.000318	0.0128	CbGeAlD
Phentolamine—ADRA2C—nervous system—epilepsy syndrome	0.000315	0.0127	CbGeAlD
Phentolamine—ADRA1A—cerebellum—epilepsy syndrome	0.000311	0.0125	CbGeAlD
Phentolamine—SIGMAR1—brain—epilepsy syndrome	0.000307	0.0123	CbGeAlD
Phentolamine—ADRA2A—midbrain—epilepsy syndrome	0.000306	0.0123	CbGeAlD
Phentolamine—ADRA2C—central nervous system—epilepsy syndrome	0.000303	0.0122	CbGeAlD
Phentolamine—ADRA2A—spinal cord—epilepsy syndrome	0.000298	0.012	CbGeAlD
Phentolamine—Nervous system disorder—Clonazepam—epilepsy syndrome	0.000297	0.00185	CcSEcCtD
Phentolamine—ADRA2C—cerebellum—epilepsy syndrome	0.000297	0.0119	CbGeAlD
Phentolamine—Dizziness—Clobazam—epilepsy syndrome	0.000296	0.00185	CcSEcCtD
Phentolamine—Tachycardia—Clonazepam—epilepsy syndrome	0.000295	0.00185	CcSEcCtD
Phentolamine—Nervous system disorder—Phenytoin—epilepsy syndrome	0.000295	0.00184	CcSEcCtD
Phentolamine—Hypotension—Zonisamide—epilepsy syndrome	0.000294	0.00183	CcSEcCtD
Phentolamine—Tachycardia—Phenytoin—epilepsy syndrome	0.000294	0.00183	CcSEcCtD
Phentolamine—Hypertension—Lamotrigine—epilepsy syndrome	0.000293	0.00183	CcSEcCtD
Phentolamine—Nervous system disorder—Oxcarbazepine—epilepsy syndrome	0.000293	0.00183	CcSEcCtD
Phentolamine—Vomiting—Lacosamide—epilepsy syndrome	0.000293	0.00183	CcSEcCtD
Phentolamine—Abdominal pain—Propofol—epilepsy syndrome	0.000293	0.00183	CcSEcCtD
Phentolamine—Gastrointestinal pain—Levetiracetam—epilepsy syndrome	0.000293	0.00183	CcSEcCtD
Phentolamine—Tachycardia—Oxcarbazepine—epilepsy syndrome	0.000292	0.00182	CcSEcCtD
Phentolamine—Nausea—Rufinamide—epilepsy syndrome	0.000292	0.00182	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Vigabatrin—epilepsy syndrome	0.000291	0.00182	CcSEcCtD
Phentolamine—Chest pain—Lamotrigine—epilepsy syndrome	0.000289	0.00181	CcSEcCtD
Phentolamine—Headache—Lacosamide—epilepsy syndrome	0.000289	0.00181	CcSEcCtD
Phentolamine—Paraesthesia—Felbamate—epilepsy syndrome	0.000288	0.0018	CcSEcCtD
Phentolamine—Pain—Vigabatrin—epilepsy syndrome	0.000288	0.0018	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Diazepam—epilepsy syndrome	0.000286	0.00179	CcSEcCtD
Phentolamine—Asthenia—Acetazolamide—epilepsy syndrome	0.000286	0.00179	CcSEcCtD
Phentolamine—Abdominal pain upper—Topiramate—epilepsy syndrome	0.000286	0.00179	CcSEcCtD
Phentolamine—Orthostatic hypotension—Topiramate—epilepsy syndrome	0.000286	0.00179	CcSEcCtD
Phentolamine—Bradycardia—Pregabalin—epilepsy syndrome	0.000286	0.00178	CcSEcCtD
Phentolamine—Vomiting—Clobazam—epilepsy syndrome	0.000285	0.00178	CcSEcCtD
Phentolamine—Pain—Diazepam—epilepsy syndrome	0.000284	0.00177	CcSEcCtD
Phentolamine—Abdominal pain—Levetiracetam—epilepsy syndrome	0.000283	0.00177	CcSEcCtD
Phentolamine—Hypotension—Clonazepam—epilepsy syndrome	0.000283	0.00177	CcSEcCtD
Phentolamine—Acute coronary syndrome—Gabapentin—epilepsy syndrome	0.000282	0.00176	CcSEcCtD
Phentolamine—Paraesthesia—Zonisamide—epilepsy syndrome	0.000282	0.00176	CcSEcCtD
Phentolamine—Angiopathy—Valproic Acid—epilepsy syndrome	0.000282	0.00176	CcSEcCtD
Phentolamine—Nervous system disorder—Carbamazepine—epilepsy syndrome	0.000282	0.00176	CcSEcCtD
Phentolamine—Hypotension—Phenytoin—epilepsy syndrome	0.000281	0.00176	CcSEcCtD
Phentolamine—Myocardial infarction—Gabapentin—epilepsy syndrome	0.000281	0.00175	CcSEcCtD
Phentolamine—Headache—Clobazam—epilepsy syndrome	0.00028	0.00175	CcSEcCtD
Phentolamine—Tachycardia—Carbamazepine—epilepsy syndrome	0.00028	0.00175	CcSEcCtD
Phentolamine—Mediastinal disorder—Valproic Acid—epilepsy syndrome	0.00028	0.00175	CcSEcCtD
Phentolamine—Hypotension—Oxcarbazepine—epilepsy syndrome	0.00028	0.00175	CcSEcCtD
Phentolamine—Arrhythmia—Valproic Acid—epilepsy syndrome	0.000277	0.00173	CcSEcCtD
Phentolamine—Gastrointestinal pain—Vigabatrin—epilepsy syndrome	0.000275	0.00172	CcSEcCtD
Phentolamine—Pain—Felbamate—epilepsy syndrome	0.000274	0.00171	CcSEcCtD
Phentolamine—Nausea—Lacosamide—epilepsy syndrome	0.000274	0.00171	CcSEcCtD
Phentolamine—Diarrhoea—Acetazolamide—epilepsy syndrome	0.000273	0.00171	CcSEcCtD
Phentolamine—Nervous system disorder—Lamotrigine—epilepsy syndrome	0.000272	0.0017	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Zonisamide—epilepsy syndrome	0.000271	0.00169	CcSEcCtD
Phentolamine—Gastrointestinal pain—Diazepam—epilepsy syndrome	0.000271	0.00169	CcSEcCtD
Phentolamine—Tachycardia—Lamotrigine—epilepsy syndrome	0.000271	0.00169	CcSEcCtD
Phentolamine—Paraesthesia—Phenytoin—epilepsy syndrome	0.00027	0.00169	CcSEcCtD
Phentolamine—Hypotension—Carbamazepine—epilepsy syndrome	0.000268	0.00168	CcSEcCtD
Phentolamine—Abdominal pain—Vigabatrin—epilepsy syndrome	0.000266	0.00166	CcSEcCtD
Phentolamine—Nausea—Clobazam—epilepsy syndrome	0.000266	0.00166	CcSEcCtD
Phentolamine—Asthenia—Propofol—epilepsy syndrome	0.000266	0.00166	CcSEcCtD
Phentolamine—ADRA2A—head—epilepsy syndrome	0.000265	0.0106	CbGeAlD
Phentolamine—Dizziness—Acetazolamide—epilepsy syndrome	0.000264	0.00165	CcSEcCtD
Phentolamine—Angina pectoris—Topiramate—epilepsy syndrome	0.000263	0.00165	CcSEcCtD
Phentolamine—Gastrointestinal pain—Felbamate—epilepsy syndrome	0.000262	0.00164	CcSEcCtD
Phentolamine—Pruritus—Propofol—epilepsy syndrome	0.000262	0.00164	CcSEcCtD
Phentolamine—Abdominal pain—Diazepam—epilepsy syndrome	0.000262	0.00164	CcSEcCtD
Phentolamine—Bradycardia—Gabapentin—epilepsy syndrome	0.000262	0.00164	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Clonazepam—epilepsy syndrome	0.000261	0.00163	CcSEcCtD
Phentolamine—Flushing—Pregabalin—epilepsy syndrome	0.00026	0.00163	CcSEcCtD
Phentolamine—Cardiac disorder—Pregabalin—epilepsy syndrome	0.00026	0.00163	CcSEcCtD
Phentolamine—Asthenia—Midazolam—epilepsy syndrome	0.00026	0.00163	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Phenytoin—epilepsy syndrome	0.00026	0.00162	CcSEcCtD
Phentolamine—Pain—Clonazepam—epilepsy syndrome	0.000259	0.00162	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Oxcarbazepine—epilepsy syndrome	0.000258	0.00161	CcSEcCtD
Phentolamine—Paraesthesia—Carbamazepine—epilepsy syndrome	0.000258	0.00161	CcSEcCtD
Phentolamine—Gastrointestinal pain—Zonisamide—epilepsy syndrome	0.000257	0.0016	CcSEcCtD
Phentolamine—Asthenia—Levetiracetam—epilepsy syndrome	0.000257	0.0016	CcSEcCtD
Phentolamine—Pruritus—Midazolam—epilepsy syndrome	0.000257	0.0016	CcSEcCtD
Phentolamine—Pain—Oxcarbazepine—epilepsy syndrome	0.000256	0.0016	CcSEcCtD
Phentolamine—Angiopathy—Pregabalin—epilepsy syndrome	0.000255	0.00159	CcSEcCtD
Phentolamine—Abdominal pain—Felbamate—epilepsy syndrome	0.000254	0.00158	CcSEcCtD
Phentolamine—Vomiting—Acetazolamide—epilepsy syndrome	0.000254	0.00158	CcSEcCtD
Phentolamine—Diarrhoea—Propofol—epilepsy syndrome	0.000254	0.00158	CcSEcCtD
Phentolamine—Pruritus—Levetiracetam—epilepsy syndrome	0.000253	0.00158	CcSEcCtD
Phentolamine—Mediastinal disorder—Pregabalin—epilepsy syndrome	0.000253	0.00158	CcSEcCtD
Phentolamine—ADRA1A—brain—epilepsy syndrome	0.000253	0.0101	CbGeAlD
Phentolamine—ADRA2A—nervous system—epilepsy syndrome	0.000251	0.0101	CbGeAlD
Phentolamine—Arrhythmia—Pregabalin—epilepsy syndrome	0.000251	0.00157	CcSEcCtD
Phentolamine—Headache—Acetazolamide—epilepsy syndrome	0.00025	0.00156	CcSEcCtD
Phentolamine—Paraesthesia—Lamotrigine—epilepsy syndrome	0.000249	0.00156	CcSEcCtD
Phentolamine—Abdominal pain—Zonisamide—epilepsy syndrome	0.000248	0.00155	CcSEcCtD
Phentolamine—Asthenia—Fosphenytoin—epilepsy syndrome	0.000248	0.00155	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	0.000248	0.00155	CcSEcCtD
Phentolamine—Gastrointestinal pain—Clonazepam—epilepsy syndrome	0.000248	0.00155	CcSEcCtD
Phentolamine—Pain—Carbamazepine—epilepsy syndrome	0.000245	0.00153	CcSEcCtD
Phentolamine—Dizziness—Propofol—epilepsy syndrome	0.000245	0.00153	CcSEcCtD
Phentolamine—Diarrhoea—Levetiracetam—epilepsy syndrome	0.000245	0.00153	CcSEcCtD
Phentolamine—Gastrointestinal pain—Oxcarbazepine—epilepsy syndrome	0.000245	0.00153	CcSEcCtD
Phentolamine—Pruritus—Fosphenytoin—epilepsy syndrome	0.000244	0.00153	CcSEcCtD
Phentolamine—ADRA2A—central nervous system—epilepsy syndrome	0.000242	0.00972	CbGeAlD
Phentolamine—Asthenia—Vigabatrin—epilepsy syndrome	0.000242	0.00151	CcSEcCtD
Phentolamine—ADRA2C—brain—epilepsy syndrome	0.000241	0.00967	CbGeAlD
Phentolamine—Dizziness—Midazolam—epilepsy syndrome	0.00024	0.0015	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	0.00024	0.0015	CcSEcCtD
Phentolamine—Abdominal pain—Clonazepam—epilepsy syndrome	0.000239	0.0015	CcSEcCtD
Phentolamine—Cardiac disorder—Gabapentin—epilepsy syndrome	0.000239	0.00149	CcSEcCtD
Phentolamine—Pruritus—Vigabatrin—epilepsy syndrome	0.000238	0.00149	CcSEcCtD
Phentolamine—Asthenia—Diazepam—epilepsy syndrome	0.000238	0.00149	CcSEcCtD
Phentolamine—Pain—Lamotrigine—epilepsy syndrome	0.000237	0.00148	CcSEcCtD
Phentolamine—Nausea—Acetazolamide—epilepsy syndrome	0.000237	0.00148	CcSEcCtD
Phentolamine—Dizziness—Levetiracetam—epilepsy syndrome	0.000237	0.00148	CcSEcCtD
Phentolamine—ADRA2A—cerebellum—epilepsy syndrome	0.000237	0.0095	CbGeAlD
Phentolamine—Abdominal pain—Oxcarbazepine—epilepsy syndrome	0.000236	0.00148	CcSEcCtD
Phentolamine—Diarrhoea—Fosphenytoin—epilepsy syndrome	0.000236	0.00148	CcSEcCtD
Phentolamine—Vomiting—Propofol—epilepsy syndrome	0.000236	0.00147	CcSEcCtD
Phentolamine—Gastrointestinal pain—Carbamazepine—epilepsy syndrome	0.000235	0.00147	CcSEcCtD
Phentolamine—Pruritus—Diazepam—epilepsy syndrome	0.000235	0.00147	CcSEcCtD
Phentolamine—Hypertension—Valproic Acid—epilepsy syndrome	0.000233	0.00146	CcSEcCtD
Phentolamine—Headache—Propofol—epilepsy syndrome	0.000232	0.00145	CcSEcCtD
Phentolamine—Mediastinal disorder—Gabapentin—epilepsy syndrome	0.000232	0.00145	CcSEcCtD
Phentolamine—Vomiting—Midazolam—epilepsy syndrome	0.000231	0.00144	CcSEcCtD
Phentolamine—Diarrhoea—Vigabatrin—epilepsy syndrome	0.00023	0.00144	CcSEcCtD
Phentolamine—Asthenia—Felbamate—epilepsy syndrome	0.00023	0.00144	CcSEcCtD
Phentolamine—Chest pain—Valproic Acid—epilepsy syndrome	0.00023	0.00144	CcSEcCtD
Phentolamine—Dizziness—Fosphenytoin—epilepsy syndrome	0.000228	0.00143	CcSEcCtD
Phentolamine—Vomiting—Levetiracetam—epilepsy syndrome	0.000228	0.00142	CcSEcCtD
Phentolamine—Headache—Midazolam—epilepsy syndrome	0.000227	0.00142	CcSEcCtD
Phentolamine—Pruritus—Felbamate—epilepsy syndrome	0.000227	0.00142	CcSEcCtD
Phentolamine—Abdominal pain—Carbamazepine—epilepsy syndrome	0.000227	0.00142	CcSEcCtD
Phentolamine—Diarrhoea—Diazepam—epilepsy syndrome	0.000227	0.00142	CcSEcCtD
Phentolamine—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	0.000227	0.00142	CcSEcCtD
Phentolamine—Asthenia—Zonisamide—epilepsy syndrome	0.000225	0.00141	CcSEcCtD
Phentolamine—Headache—Levetiracetam—epilepsy syndrome	0.000224	0.0014	CcSEcCtD
Phentolamine—Dizziness—Vigabatrin—epilepsy syndrome	0.000223	0.00139	CcSEcCtD
Phentolamine—Pruritus—Zonisamide—epilepsy syndrome	0.000222	0.00139	CcSEcCtD
Phentolamine—Bradycardia—Topiramate—epilepsy syndrome	0.00022	0.00138	CcSEcCtD
Phentolamine—Nausea—Propofol—epilepsy syndrome	0.00022	0.00138	CcSEcCtD
Phentolamine—Vomiting—Fosphenytoin—epilepsy syndrome	0.00022	0.00137	CcSEcCtD
Phentolamine—Diarrhoea—Felbamate—epilepsy syndrome	0.00022	0.00137	CcSEcCtD
Phentolamine—Abdominal pain—Lamotrigine—epilepsy syndrome	0.000219	0.00137	CcSEcCtD
Phentolamine—Dizziness—Diazepam—epilepsy syndrome	0.000219	0.00137	CcSEcCtD
Phentolamine—Asthenia—Clonazepam—epilepsy syndrome	0.000217	0.00136	CcSEcCtD
Phentolamine—Headache—Fosphenytoin—epilepsy syndrome	0.000216	0.00135	CcSEcCtD
Phentolamine—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.000216	0.00135	CcSEcCtD
Phentolamine—Asthenia—Phenytoin—epilepsy syndrome	0.000216	0.00135	CcSEcCtD
Phentolamine—Nausea—Midazolam—epilepsy syndrome	0.000215	0.00135	CcSEcCtD
Phentolamine—Tachycardia—Valproic Acid—epilepsy syndrome	0.000215	0.00134	CcSEcCtD
Phentolamine—Diarrhoea—Zonisamide—epilepsy syndrome	0.000215	0.00134	CcSEcCtD
Phentolamine—Asthenia—Oxcarbazepine—epilepsy syndrome	0.000215	0.00134	CcSEcCtD
Phentolamine—Pruritus—Clonazepam—epilepsy syndrome	0.000214	0.00134	CcSEcCtD
Phentolamine—Vomiting—Vigabatrin—epilepsy syndrome	0.000214	0.00134	CcSEcCtD
Phentolamine—Pruritus—Phenytoin—epilepsy syndrome	0.000213	0.00133	CcSEcCtD
Phentolamine—Nausea—Levetiracetam—epilepsy syndrome	0.000213	0.00133	CcSEcCtD
Phentolamine—Dizziness—Felbamate—epilepsy syndrome	0.000212	0.00133	CcSEcCtD
Phentolamine—Pruritus—Oxcarbazepine—epilepsy syndrome	0.000212	0.00132	CcSEcCtD
Phentolamine—Headache—Vigabatrin—epilepsy syndrome	0.000211	0.00132	CcSEcCtD
Phentolamine—Hypertension—Pregabalin—epilepsy syndrome	0.000211	0.00132	CcSEcCtD
Phentolamine—Vomiting—Diazepam—epilepsy syndrome	0.000211	0.00132	CcSEcCtD
Phentolamine—Chest pain—Pregabalin—epilepsy syndrome	0.000208	0.0013	CcSEcCtD
Phentolamine—Dizziness—Zonisamide—epilepsy syndrome	0.000208	0.0013	CcSEcCtD
Phentolamine—Headache—Diazepam—epilepsy syndrome	0.000208	0.0013	CcSEcCtD
Phentolamine—Diarrhoea—Clonazepam—epilepsy syndrome	0.000207	0.00129	CcSEcCtD
Phentolamine—Hypotension—Valproic Acid—epilepsy syndrome	0.000206	0.00129	CcSEcCtD
Phentolamine—Asthenia—Carbamazepine—epilepsy syndrome	0.000206	0.00129	CcSEcCtD
Phentolamine—Diarrhoea—Phenytoin—epilepsy syndrome	0.000206	0.00129	CcSEcCtD
Phentolamine—Nausea—Fosphenytoin—epilepsy syndrome	0.000205	0.00128	CcSEcCtD
Phentolamine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.000205	0.00128	CcSEcCtD
Phentolamine—Vomiting—Felbamate—epilepsy syndrome	0.000204	0.00127	CcSEcCtD
Phentolamine—Pruritus—Carbamazepine—epilepsy syndrome	0.000203	0.00127	CcSEcCtD
Phentolamine—Headache—Felbamate—epilepsy syndrome	0.000201	0.00126	CcSEcCtD
Phentolamine—Flushing—Topiramate—epilepsy syndrome	0.000201	0.00125	CcSEcCtD
Phentolamine—Cardiac disorder—Topiramate—epilepsy syndrome	0.000201	0.00125	CcSEcCtD
Phentolamine—Dizziness—Clonazepam—epilepsy syndrome	0.0002	0.00125	CcSEcCtD
Phentolamine—Nausea—Vigabatrin—epilepsy syndrome	0.0002	0.00125	CcSEcCtD
Phentolamine—Vomiting—Zonisamide—epilepsy syndrome	0.0002	0.00125	CcSEcCtD
Phentolamine—Asthenia—Lamotrigine—epilepsy syndrome	0.000199	0.00124	CcSEcCtD
Phentolamine—Dizziness—Phenytoin—epilepsy syndrome	0.000199	0.00124	CcSEcCtD
Phentolamine—Paraesthesia—Valproic Acid—epilepsy syndrome	0.000198	0.00124	CcSEcCtD
Phentolamine—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000198	0.00124	CcSEcCtD
Phentolamine—Nausea—Diazepam—epilepsy syndrome	0.000197	0.00123	CcSEcCtD
Phentolamine—Headache—Zonisamide—epilepsy syndrome	0.000197	0.00123	CcSEcCtD
Phentolamine—Diarrhoea—Carbamazepine—epilepsy syndrome	0.000196	0.00123	CcSEcCtD
Phentolamine—Angiopathy—Topiramate—epilepsy syndrome	0.000196	0.00123	CcSEcCtD
Phentolamine—Pruritus—Lamotrigine—epilepsy syndrome	0.000196	0.00123	CcSEcCtD
Phentolamine—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000195	0.00122	CcSEcCtD
Phentolamine—Mediastinal disorder—Topiramate—epilepsy syndrome	0.000195	0.00122	CcSEcCtD
Phentolamine—Tachycardia—Pregabalin—epilepsy syndrome	0.000195	0.00122	CcSEcCtD
Phentolamine—Hypertension—Gabapentin—epilepsy syndrome	0.000193	0.00121	CcSEcCtD
Phentolamine—Vomiting—Clonazepam—epilepsy syndrome	0.000193	0.0012	CcSEcCtD
Phentolamine—ADRA2A—brain—epilepsy syndrome	0.000192	0.00772	CbGeAlD
Phentolamine—Vomiting—Phenytoin—epilepsy syndrome	0.000191	0.00119	CcSEcCtD
Phentolamine—Chest pain—Gabapentin—epilepsy syndrome	0.000191	0.00119	CcSEcCtD
Phentolamine—Nausea—Felbamate—epilepsy syndrome	0.000191	0.00119	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.00019	0.00119	CcSEcCtD
Phentolamine—Vomiting—Oxcarbazepine—epilepsy syndrome	0.00019	0.00119	CcSEcCtD
Phentolamine—Dizziness—Carbamazepine—epilepsy syndrome	0.00019	0.00119	CcSEcCtD
Phentolamine—Diarrhoea—Lamotrigine—epilepsy syndrome	0.00019	0.00119	CcSEcCtD
Phentolamine—Headache—Clonazepam—epilepsy syndrome	0.00019	0.00118	CcSEcCtD
Phentolamine—Pain—Valproic Acid—epilepsy syndrome	0.000189	0.00118	CcSEcCtD
Phentolamine—Headache—Phenytoin—epilepsy syndrome	0.000188	0.00118	CcSEcCtD
Phentolamine—Headache—Oxcarbazepine—epilepsy syndrome	0.000187	0.00117	CcSEcCtD
Phentolamine—Nausea—Zonisamide—epilepsy syndrome	0.000187	0.00117	CcSEcCtD
Phentolamine—Hypotension—Pregabalin—epilepsy syndrome	0.000186	0.00116	CcSEcCtD
Phentolamine—Dizziness—Lamotrigine—epilepsy syndrome	0.000183	0.00115	CcSEcCtD
Phentolamine—Vomiting—Carbamazepine—epilepsy syndrome	0.000183	0.00114	CcSEcCtD
Phentolamine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	0.00018	0.00113	CcSEcCtD
Phentolamine—Nausea—Clonazepam—epilepsy syndrome	0.00018	0.00112	CcSEcCtD
Phentolamine—Headache—Carbamazepine—epilepsy syndrome	0.00018	0.00112	CcSEcCtD
Phentolamine—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000179	0.00112	CcSEcCtD
Phentolamine—Paraesthesia—Pregabalin—epilepsy syndrome	0.000179	0.00112	CcSEcCtD
Phentolamine—Nausea—Phenytoin—epilepsy syndrome	0.000179	0.00112	CcSEcCtD
Phentolamine—Tachycardia—Gabapentin—epilepsy syndrome	0.000178	0.00111	CcSEcCtD
Phentolamine—Nausea—Oxcarbazepine—epilepsy syndrome	0.000178	0.00111	CcSEcCtD
Phentolamine—Vomiting—Lamotrigine—epilepsy syndrome	0.000176	0.0011	CcSEcCtD
Phentolamine—Abdominal pain—Valproic Acid—epilepsy syndrome	0.000174	0.00109	CcSEcCtD
Phentolamine—Headache—Lamotrigine—epilepsy syndrome	0.000174	0.00109	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	0.000172	0.00107	CcSEcCtD
Phentolamine—Hypotension—Gabapentin—epilepsy syndrome	0.000171	0.00107	CcSEcCtD
Phentolamine—Nausea—Carbamazepine—epilepsy syndrome	0.000171	0.00107	CcSEcCtD
Phentolamine—Pain—Pregabalin—epilepsy syndrome	0.00017	0.00106	CcSEcCtD
Phentolamine—Nausea—Lamotrigine—epilepsy syndrome	0.000165	0.00103	CcSEcCtD
Phentolamine—Paraesthesia—Gabapentin—epilepsy syndrome	0.000164	0.00103	CcSEcCtD
Phentolamine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	0.000163	0.00102	CcSEcCtD
Phentolamine—Hypertension—Topiramate—epilepsy syndrome	0.000163	0.00102	CcSEcCtD
Phentolamine—Chest pain—Topiramate—epilepsy syndrome	0.00016	0.001	CcSEcCtD
Phentolamine—Asthenia—Valproic Acid—epilepsy syndrome	0.000158	0.000988	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	0.000158	0.000986	CcSEcCtD
Phentolamine—Abdominal pain—Pregabalin—epilepsy syndrome	0.000158	0.000984	CcSEcCtD
Phentolamine—Pain—Gabapentin—epilepsy syndrome	0.000156	0.000976	CcSEcCtD
Phentolamine—Pruritus—Valproic Acid—epilepsy syndrome	0.000156	0.000974	CcSEcCtD
Phentolamine—Diarrhoea—Valproic Acid—epilepsy syndrome	0.000151	0.000942	CcSEcCtD
Phentolamine—Nervous system disorder—Topiramate—epilepsy syndrome	0.000151	0.000942	CcSEcCtD
Phentolamine—Tachycardia—Topiramate—epilepsy syndrome	0.00015	0.000938	CcSEcCtD
Phentolamine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	0.000149	0.000934	CcSEcCtD
Phentolamine—Dizziness—Valproic Acid—epilepsy syndrome	0.000146	0.000911	CcSEcCtD
Phentolamine—Abdominal pain—Gabapentin—epilepsy syndrome	0.000144	0.000903	CcSEcCtD
Phentolamine—Hypotension—Topiramate—epilepsy syndrome	0.000144	0.000898	CcSEcCtD
Phentolamine—Asthenia—Pregabalin—epilepsy syndrome	0.000143	0.000893	CcSEcCtD
Phentolamine—Pruritus—Pregabalin—epilepsy syndrome	0.000141	0.000881	CcSEcCtD
Phentolamine—Vomiting—Valproic Acid—epilepsy syndrome	0.00014	0.000876	CcSEcCtD
Phentolamine—Headache—Valproic Acid—epilepsy syndrome	0.000138	0.000863	CcSEcCtD
Phentolamine—Paraesthesia—Topiramate—epilepsy syndrome	0.000138	0.000863	CcSEcCtD
Phentolamine—Diarrhoea—Pregabalin—epilepsy syndrome	0.000136	0.000852	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	0.000133	0.000829	CcSEcCtD
Phentolamine—Dizziness—Pregabalin—epilepsy syndrome	0.000132	0.000823	CcSEcCtD
Phentolamine—Pain—Topiramate—epilepsy syndrome	0.000131	0.000821	CcSEcCtD
Phentolamine—Asthenia—Gabapentin—epilepsy syndrome	0.000131	0.000819	CcSEcCtD
Phentolamine—Nausea—Valproic Acid—epilepsy syndrome	0.000131	0.000818	CcSEcCtD
Phentolamine—Pruritus—Gabapentin—epilepsy syndrome	0.000129	0.000808	CcSEcCtD
Phentolamine—Vomiting—Pregabalin—epilepsy syndrome	0.000127	0.000792	CcSEcCtD
Phentolamine—Gastrointestinal pain—Topiramate—epilepsy syndrome	0.000126	0.000785	CcSEcCtD
Phentolamine—Diarrhoea—Gabapentin—epilepsy syndrome	0.000125	0.000781	CcSEcCtD
Phentolamine—Headache—Pregabalin—epilepsy syndrome	0.000125	0.00078	CcSEcCtD
Phentolamine—Abdominal pain—Topiramate—epilepsy syndrome	0.000122	0.000759	CcSEcCtD
Phentolamine—Dizziness—Gabapentin—epilepsy syndrome	0.000121	0.000755	CcSEcCtD
Phentolamine—Nausea—Pregabalin—epilepsy syndrome	0.000118	0.00074	CcSEcCtD
Phentolamine—Vomiting—Gabapentin—epilepsy syndrome	0.000116	0.000726	CcSEcCtD
Phentolamine—Headache—Gabapentin—epilepsy syndrome	0.000114	0.000715	CcSEcCtD
Phentolamine—Asthenia—Topiramate—epilepsy syndrome	0.00011	0.000689	CcSEcCtD
Phentolamine—Pruritus—Topiramate—epilepsy syndrome	0.000109	0.00068	CcSEcCtD
Phentolamine—Nausea—Gabapentin—epilepsy syndrome	0.000109	0.000678	CcSEcCtD
Phentolamine—Diarrhoea—Topiramate—epilepsy syndrome	0.000105	0.000657	CcSEcCtD
Phentolamine—Dizziness—Topiramate—epilepsy syndrome	0.000102	0.000635	CcSEcCtD
Phentolamine—Vomiting—Topiramate—epilepsy syndrome	9.78e-05	0.000611	CcSEcCtD
Phentolamine—Headache—Topiramate—epilepsy syndrome	9.63e-05	0.000602	CcSEcCtD
Phentolamine—Nausea—Topiramate—epilepsy syndrome	9.13e-05	0.000571	CcSEcCtD
Phentolamine—ADRA1A—Signaling Pathways—ADRA2A—epilepsy syndrome	7.23e-06	5.78e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—POMC—epilepsy syndrome	7.21e-06	5.76e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PLAT—epilepsy syndrome	7.2e-06	5.75e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HES1—epilepsy syndrome	7.18e-06	5.74e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—S100B—epilepsy syndrome	7.17e-06	5.73e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT3—epilepsy syndrome	7.14e-06	5.7e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SOCS3—epilepsy syndrome	7.1e-06	5.67e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—POMC—epilepsy syndrome	7.09e-06	5.67e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CDC42—epilepsy syndrome	7.09e-06	5.66e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ADAM10—epilepsy syndrome	7.09e-06	5.66e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	7.08e-06	5.65e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TSC1—epilepsy syndrome	7.06e-06	5.64e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PTK2B—epilepsy syndrome	7.06e-06	5.64e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CCL2—epilepsy syndrome	7.05e-06	5.63e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—FYN—epilepsy syndrome	6.99e-06	5.58e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ADAM10—epilepsy syndrome	6.97e-06	5.57e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—H2AFX—epilepsy syndrome	6.96e-06	5.56e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AGT—epilepsy syndrome	6.96e-06	5.55e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MEF2C—epilepsy syndrome	6.95e-06	5.55e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CXCL12—epilepsy syndrome	6.95e-06	5.55e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—BDKRB2—epilepsy syndrome	6.95e-06	5.55e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CCL2—epilepsy syndrome	6.94e-06	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—POMC—epilepsy syndrome	6.94e-06	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PRKCB—epilepsy syndrome	6.92e-06	5.52e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—GPX1—epilepsy syndrome	6.9e-06	5.51e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL6ST—epilepsy syndrome	6.89e-06	5.5e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NTRK2—epilepsy syndrome	6.87e-06	5.48e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCR2—epilepsy syndrome	6.87e-06	5.48e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SST—epilepsy syndrome	6.87e-06	5.48e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AVP—epilepsy syndrome	6.86e-06	5.48e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—JUNB—epilepsy syndrome	6.82e-06	5.45e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CNR1—epilepsy syndrome	6.82e-06	5.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DUSP6—epilepsy syndrome	6.81e-06	5.44e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PLCB1—epilepsy syndrome	6.8e-06	5.43e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—YWHAZ—epilepsy syndrome	6.72e-06	5.36e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—S100B—epilepsy syndrome	6.7e-06	5.35e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PLAT—epilepsy syndrome	6.69e-06	5.34e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HTR7—epilepsy syndrome	6.65e-06	5.31e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NGF—epilepsy syndrome	6.64e-06	5.3e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SOCS3—epilepsy syndrome	6.63e-06	5.3e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CDC42—epilepsy syndrome	6.62e-06	5.29e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—S100B—epilepsy syndrome	6.59e-06	5.27e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—SRC—epilepsy syndrome	6.58e-06	5.26e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SOCS3—epilepsy syndrome	6.53e-06	5.21e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CDC42—epilepsy syndrome	6.51e-06	5.2e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HES1—epilepsy syndrome	6.49e-06	5.18e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCR5—epilepsy syndrome	6.46e-06	5.16e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HBEGF—epilepsy syndrome	6.46e-06	5.16e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—BDKRB2—epilepsy syndrome	6.46e-06	5.16e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CXCL12—epilepsy syndrome	6.46e-06	5.16e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—POMC—epilepsy syndrome	6.45e-06	5.15e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PRKCB—epilepsy syndrome	6.43e-06	5.13e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—VEGFA—epilepsy syndrome	6.41e-06	5.12e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AVP—epilepsy syndrome	6.41e-06	5.12e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL6ST—epilepsy syndrome	6.4e-06	5.11e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT3—epilepsy syndrome	6.34e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—JUNB—epilepsy syndrome	6.34e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CNR1—epilepsy syndrome	6.34e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HTR2A—epilepsy syndrome	6.32e-06	5.05e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PLCB1—epilepsy syndrome	6.31e-06	5.04e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—FYN—epilepsy syndrome	6.31e-06	5.04e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AVP—epilepsy syndrome	6.31e-06	5.04e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—POMC—epilepsy syndrome	6.3e-06	5.03e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—H2AFX—epilepsy syndrome	6.28e-06	5.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—HMOX1—epilepsy syndrome	6.28e-06	5.02e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MEF2C—epilepsy syndrome	6.27e-06	5.01e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CAT—epilepsy syndrome	6.2e-06	4.95e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ADAM10—epilepsy syndrome	6.19e-06	4.95e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HTR7—epilepsy syndrome	6.18e-06	4.94e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CCL2—epilepsy syndrome	6.17e-06	4.92e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—YWHAZ—epilepsy syndrome	6.06e-06	4.84e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HES1—epilepsy syndrome	6.06e-06	4.84e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AGT—epilepsy syndrome	6.05e-06	4.83e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ABCB1—epilepsy syndrome	6.03e-06	4.81e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TSC2—epilepsy syndrome	6.01e-06	4.8e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HBEGF—epilepsy syndrome	6e-06	4.79e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AGT—epilepsy syndrome	6e-06	4.79e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NGF—epilepsy syndrome	6e-06	4.79e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HES1—epilepsy syndrome	5.96e-06	4.76e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—APOE—epilepsy syndrome	5.93e-06	4.73e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT3—epilepsy syndrome	5.89e-06	4.71e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—FYN—epilepsy syndrome	5.89e-06	4.71e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—APOE—epilepsy syndrome	5.88e-06	4.69e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—H2AFX—epilepsy syndrome	5.87e-06	4.69e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MEF2C—epilepsy syndrome	5.86e-06	4.68e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—S100B—epilepsy syndrome	5.86e-06	4.68e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—POMC—epilepsy syndrome	5.85e-06	4.68e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCR5—epilepsy syndrome	5.83e-06	4.66e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SOCS3—epilepsy syndrome	5.8e-06	4.63e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—FYN—epilepsy syndrome	5.8e-06	4.63e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDC42—epilepsy syndrome	5.79e-06	4.62e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—H2AFX—epilepsy syndrome	5.78e-06	4.61e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MEF2C—epilepsy syndrome	5.77e-06	4.61e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—KDR—epilepsy syndrome	5.76e-06	4.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ADAM10—epilepsy syndrome	5.75e-06	4.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CCL2—epilepsy syndrome	5.73e-06	4.57e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HTR2A—epilepsy syndrome	5.71e-06	4.56e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—YWHAZ—epilepsy syndrome	5.66e-06	4.52e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—GPX1—epilepsy syndrome	5.6e-06	4.48e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AVP—epilepsy syndrome	5.6e-06	4.47e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NGF—epilepsy syndrome	5.6e-06	4.47e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—YWHAZ—epilepsy syndrome	5.57e-06	4.45e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PRKCB—epilepsy syndrome	5.54e-06	4.43e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL6ST—epilepsy syndrome	5.52e-06	4.41e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NGF—epilepsy syndrome	5.51e-06	4.4e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCR5—epilepsy syndrome	5.45e-06	4.35e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—S100B—epilepsy syndrome	5.44e-06	4.35e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TSC2—epilepsy syndrome	5.42e-06	4.33e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AGT—epilepsy syndrome	5.42e-06	4.33e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—AKT1—epilepsy syndrome	5.39e-06	4.3e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SOCS3—epilepsy syndrome	5.39e-06	4.3e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDC42—epilepsy syndrome	5.38e-06	4.29e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCR5—epilepsy syndrome	5.36e-06	4.28e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HTR2A—epilepsy syndrome	5.33e-06	4.26e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—APOE—epilepsy syndrome	5.31e-06	4.24e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HES1—epilepsy syndrome	5.3e-06	4.23e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HTR2A—epilepsy syndrome	5.25e-06	4.19e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AVP—epilepsy syndrome	5.2e-06	4.16e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—KDR—epilepsy syndrome	5.2e-06	4.15e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—FYN—epilepsy syndrome	5.15e-06	4.11e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—H2AFX—epilepsy syndrome	5.13e-06	4.1e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MEF2C—epilepsy syndrome	5.12e-06	4.09e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—POMC—epilepsy syndrome	5.09e-06	4.07e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TSC2—epilepsy syndrome	5.06e-06	4.05e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AGT—epilepsy syndrome	5.06e-06	4.04e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—POMC—epilepsy syndrome	5.05e-06	4.03e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—AKT1—epilepsy syndrome	5.03e-06	4.02e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PRKCB—epilepsy syndrome	5e-06	4e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TSC2—epilepsy syndrome	4.98e-06	3.98e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL6ST—epilepsy syndrome	4.98e-06	3.98e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AGT—epilepsy syndrome	4.98e-06	3.98e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—APOE—epilepsy syndrome	4.96e-06	3.96e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—YWHAZ—epilepsy syndrome	4.95e-06	3.95e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCL2—epilepsy syndrome	4.94e-06	3.95e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HES1—epilepsy syndrome	4.92e-06	3.93e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AGT—epilepsy syndrome	4.91e-06	3.92e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NGF—epilepsy syndrome	4.9e-06	3.91e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—APOE—epilepsy syndrome	4.88e-06	3.9e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—KDR—epilepsy syndrome	4.86e-06	3.88e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—APOE—epilepsy syndrome	4.81e-06	3.85e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—FYN—epilepsy syndrome	4.79e-06	3.82e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—KDR—epilepsy syndrome	4.78e-06	3.82e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—H2AFX—epilepsy syndrome	4.77e-06	3.81e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCR5—epilepsy syndrome	4.76e-06	3.8e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MEF2C—epilepsy syndrome	4.76e-06	3.8e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PRKCB—epilepsy syndrome	4.67e-06	3.73e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HTR2A—epilepsy syndrome	4.66e-06	3.72e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL6ST—epilepsy syndrome	4.66e-06	3.72e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—ALB—epilepsy syndrome	4.64e-06	3.71e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	4.6e-06	3.67e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PRKCB—epilepsy syndrome	4.6e-06	3.67e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6ST—epilepsy syndrome	4.58e-06	3.66e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—POMC—epilepsy syndrome	4.56e-06	3.64e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NGF—epilepsy syndrome	4.55e-06	3.63e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—FGF2—epilepsy syndrome	4.46e-06	3.57e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCL2—epilepsy syndrome	4.46e-06	3.56e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TSC2—epilepsy syndrome	4.43e-06	3.54e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCR5—epilepsy syndrome	4.43e-06	3.53e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AGT—epilepsy syndrome	4.42e-06	3.53e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—APOE—epilepsy syndrome	4.33e-06	3.46e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HTR2A—epilepsy syndrome	4.33e-06	3.46e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—POMC—epilepsy syndrome	4.26e-06	3.4e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KDR—epilepsy syndrome	4.25e-06	3.39e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—POMC—epilepsy syndrome	4.19e-06	3.35e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCL2—epilepsy syndrome	4.17e-06	3.33e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—RELA—epilepsy syndrome	4.14e-06	3.31e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—POMC—epilepsy syndrome	4.14e-06	3.3e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TSC2—epilepsy syndrome	4.11e-06	3.29e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AGT—epilepsy syndrome	4.11e-06	3.28e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCL2—epilepsy syndrome	4.1e-06	3.27e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—AKT1—epilepsy syndrome	4.09e-06	3.27e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PRKCB—epilepsy syndrome	4.09e-06	3.26e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6ST—epilepsy syndrome	4.07e-06	3.25e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MTOR—epilepsy syndrome	4.06e-06	3.25e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTGS2—epilepsy syndrome	4.06e-06	3.24e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—FGF2—epilepsy syndrome	4.03e-06	3.22e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APOE—epilepsy syndrome	4.03e-06	3.22e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KDR—epilepsy syndrome	3.94e-06	3.15e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PRKCB—epilepsy syndrome	3.8e-06	3.03e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6ST—epilepsy syndrome	3.78e-06	3.02e-05	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—AKT1—epilepsy syndrome	3.77e-06	3.01e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ALB—epilepsy syndrome	3.77e-06	3.01e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—FGF2—epilepsy syndrome	3.77e-06	3.01e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—RELA—epilepsy syndrome	3.74e-06	2.99e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CASP3—epilepsy syndrome	3.74e-06	2.99e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—POMC—epilepsy syndrome	3.72e-06	2.97e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—FGF2—epilepsy syndrome	3.71e-06	2.96e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MTOR—epilepsy syndrome	3.67e-06	2.93e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCL2—epilepsy syndrome	3.64e-06	2.91e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—JUN—epilepsy syndrome	3.63e-06	2.9e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MMP9—epilepsy syndrome	3.53e-06	2.82e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—RELA—epilepsy syndrome	3.5e-06	2.79e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—POMC—epilepsy syndrome	3.46e-06	2.76e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—RELA—epilepsy syndrome	3.44e-06	2.75e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MTOR—epilepsy syndrome	3.43e-06	2.74e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—AKT1—epilepsy syndrome	3.43e-06	2.74e-05	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—AKT1—epilepsy syndrome	3.41e-06	2.72e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCL2—epilepsy syndrome	3.38e-06	2.7e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CASP3—epilepsy syndrome	3.38e-06	2.7e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MTOR—epilepsy syndrome	3.37e-06	2.69e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTGS2—epilepsy syndrome	3.3e-06	2.63e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—FGF2—epilepsy syndrome	3.29e-06	2.63e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—JUN—epilepsy syndrome	3.28e-06	2.62e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SRC—epilepsy syndrome	3.26e-06	2.6e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MMP9—epilepsy syndrome	3.19e-06	2.55e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—AKT1—epilepsy syndrome	3.18e-06	2.54e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—VEGFA—epilepsy syndrome	3.17e-06	2.53e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CASP3—epilepsy syndrome	3.15e-06	2.52e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—AKT1—epilepsy syndrome	3.13e-06	2.5e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CASP3—epilepsy syndrome	3.1e-06	2.48e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—AKT1—epilepsy syndrome	3.09e-06	2.47e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—JUN—epilepsy syndrome	3.06e-06	2.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—FGF2—epilepsy syndrome	3.06e-06	2.44e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—RELA—epilepsy syndrome	3.06e-06	2.44e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—JUN—epilepsy syndrome	3.01e-06	2.41e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MTOR—epilepsy syndrome	3e-06	2.39e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MMP9—epilepsy syndrome	2.98e-06	2.38e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SRC—epilepsy syndrome	2.94e-06	2.35e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MMP9—epilepsy syndrome	2.93e-06	2.34e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—AKT1—epilepsy syndrome	2.89e-06	2.31e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—VEGFA—epilepsy syndrome	2.86e-06	2.29e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—AKT1—epilepsy syndrome	2.84e-06	2.27e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—RELA—epilepsy syndrome	2.84e-06	2.27e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MTOR—epilepsy syndrome	2.78e-06	2.22e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—AKT1—epilepsy syndrome	2.78e-06	2.22e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CASP3—epilepsy syndrome	2.76e-06	2.2e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SRC—epilepsy syndrome	2.75e-06	2.19e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SRC—epilepsy syndrome	2.7e-06	2.16e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—JUN—epilepsy syndrome	2.68e-06	2.14e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—VEGFA—epilepsy syndrome	2.68e-06	2.14e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—VEGFA—epilepsy syndrome	2.63e-06	2.1e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MMP9—epilepsy syndrome	2.6e-06	2.08e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	2.58e-06	2.06e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CASP3—epilepsy syndrome	2.56e-06	2.05e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—AKT1—epilepsy syndrome	2.53e-06	2.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—JUN—epilepsy syndrome	2.49e-06	1.99e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MMP9—epilepsy syndrome	2.42e-06	1.93e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SRC—epilepsy syndrome	2.4e-06	1.92e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT1—epilepsy syndrome	2.35e-06	1.87e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—VEGFA—epilepsy syndrome	2.34e-06	1.87e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SRC—epilepsy syndrome	2.23e-06	1.78e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—VEGFA—epilepsy syndrome	2.17e-06	1.74e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AKT1—epilepsy syndrome	2.04e-06	1.63e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT1—epilepsy syndrome	2.02e-06	1.62e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT1—epilepsy syndrome	1.83e-06	1.46e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT1—epilepsy syndrome	1.71e-06	1.36e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT1—epilepsy syndrome	1.68e-06	1.34e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AKT1—epilepsy syndrome	1.66e-06	1.32e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT1—epilepsy syndrome	1.49e-06	1.19e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT1—epilepsy syndrome	1.39e-06	1.11e-05	CbGpPWpGaD
